Studies report that certain polymorphic forms of CYP enzymes such as CYP3A4 promote the rapid clearance of docetaxel from the bloodstream and lowers efficiency of cyclophosphamide in breast cancer [61]. This evidence concerns the gene CYP3A4 and breast cancer.